期刊
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
卷 10, 期 9, 页码 1037-1042出版社
WILEY
DOI: 10.1002/alr.22633
关键词
chronic rhinosinusitis; medical therapy of chronic rhinosinusitis; endoscopic sinus surgery; topical therapy for chronic rhinosinusitis; guideline
资金
- NIH/National Institute of Neurological Disorders and Stroke (NINDS) [R01 NS108968-01]
- NIH/National Institute on Deafness and Other Communication Disorders (NIDCD) [K23 DC014747]
Background Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness. Methods In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients. Results The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice. Conclusion We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long-term effects of biologics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据